Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing
Bio-Techne (NASDAQ: TECH) and Kytopen have announced a partnership to enhance cell therapy manufacturing through integrated cellular engineering workflow. The collaboration combines Bio-Techne's TcBuster™ GMP non-viral genome engineering system with Kytopen's Flowfect Tx™ GMP cellular engineering platform.
The TcBuster™ system enables simultaneous delivery of multiple genes with high editing efficiency in a single vector, while Flowfect® technology processes billions of cells in minutes using a combination of mechanical, electrical, and chemical forces. Together, these technologies aim to streamline gene delivery processes and accelerate the development of advanced cell therapies.
The companies will present their collaborative data at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting in New Orleans, May 7-10, 2025.
Bio-Techne (NASDAQ: TECH) e Kytopen hanno annunciato una partnership per migliorare la produzione di terapie cellulari tramite un flusso di lavoro integrato di ingegneria cellulare. La collaborazione unisce il sistema TcBuster™ GMP di ingegneria genomica non virale di Bio-Techne con la piattaforma di ingegneria cellulare GMP Flowfect Tx™ di Kytopen.
Il sistema TcBuster™ consente la consegna simultanea di più geni con alta efficienza di editing in un singolo vettore, mentre la tecnologia Flowfect® elabora miliardi di cellule in pochi minuti utilizzando una combinazione di forze meccaniche, elettriche e chimiche. Insieme, queste tecnologie mirano a semplificare i processi di consegna genica e accelerare lo sviluppo di terapie cellulari avanzate.
Le aziende presenteranno i dati della loro collaborazione al Congresso Annuale della International Society of Cell & Gene Therapy (ISCT) a New Orleans, dal 7 al 10 maggio 2025.
Bio-Techne (NASDAQ: TECH) y Kytopen han anunciado una alianza para mejorar la fabricación de terapias celulares mediante un flujo de trabajo integrado de ingeniería celular. La colaboración combina el sistema de ingeniería genómica no viral GMP TcBuster™ de Bio-Techne con la plataforma de ingeniería celular GMP Flowfect Tx™ de Kytopen.
El sistema TcBuster™ permite la entrega simultánea de múltiples genes con alta eficiencia de edición en un solo vector, mientras que la tecnología Flowfect® procesa miles de millones de células en minutos utilizando una combinación de fuerzas mecánicas, eléctricas y químicas. Juntas, estas tecnologías buscan optimizar los procesos de entrega genética y acelerar el desarrollo de terapias celulares avanzadas.
Las compañías presentarán sus datos colaborativos en la Reunión Anual de la International Society of Cell & Gene Therapy (ISCT) en Nueva Orleans, del 7 al 10 de mayo de 2025.
Bio-Techne (NASDAQ: TECH)와 Kytopen이 통합 세포 공학 워크플로우를 통해 세포 치료제 제조를 향상시키기 위한 파트너십을 발표했습니다. 이번 협력은 Bio-Techne의 TcBuster™ GMP 비바이러스 유전체 공학 시스템과 Kytopen의 Flowfect Tx™ GMP 세포 공학 플랫폼을 결합합니다.
TcBuster™ 시스템은 단일 벡터에서 여러 유전자를 동시에 높은 편집 효율로 전달할 수 있으며, Flowfect® 기술은 기계적, 전기적, 화학적 힘의 조합을 사용해 수십억 개의 세포를 몇 분 만에 처리합니다. 이 두 기술은 유전자 전달 과정을 간소화하고 첨단 세포 치료제 개발을 가속화하는 것을 목표로 합니다.
양사는 2025년 5월 7일부터 10일까지 뉴올리언스에서 열리는 국제 세포 및 유전자 치료 학회(ISCT) 연례회의에서 협력 데이터를 발표할 예정입니다.
Bio-Techne (NASDAQ : TECH) et Kytopen ont annoncé un partenariat visant à améliorer la fabrication de thérapies cellulaires grâce à un flux de travail intégré d’ingénierie cellulaire. Cette collaboration associe le système d’ingénierie génomique non viral GMP TcBuster™ de Bio-Techne à la plateforme d’ingénierie cellulaire GMP Flowfect Tx™ de Kytopen.
Le système TcBuster™ permet la livraison simultanée de plusieurs gènes avec une grande efficacité d’édition dans un seul vecteur, tandis que la technologie Flowfect® traite des milliards de cellules en quelques minutes grâce à une combinaison de forces mécaniques, électriques et chimiques. Ensemble, ces technologies visent à simplifier les processus de transfert génétique et à accélérer le développement de thérapies cellulaires avancées.
Les entreprises présenteront leurs données collaboratives lors de la réunion annuelle de l’International Society of Cell & Gene Therapy (ISCT) à La Nouvelle-Orléans, du 7 au 10 mai 2025.
Bio-Techne (NASDAQ: TECH) und Kytopen haben eine Partnerschaft angekündigt, um die Herstellung von Zelltherapien durch einen integrierten zellulären Engineering-Workflow zu verbessern. Die Zusammenarbeit kombiniert das TcBuster™ GMP nicht-virale Genom-Engineering-System von Bio-Techne mit der Flowfect Tx™ GMP Zell-Engineering-Plattform von Kytopen.
Das TcBuster™-System ermöglicht die gleichzeitige Übertragung mehrerer Gene mit hoher Editier-Effizienz in einem einzigen Vektor, während die Flowfect®-Technologie Milliarden von Zellen in Minuten verarbeitet, indem mechanische, elektrische und chemische Kräfte kombiniert werden. Gemeinsam zielen diese Technologien darauf ab, den Gentransfer zu optimieren und die Entwicklung fortschrittlicher Zelltherapien zu beschleunigen.
Die Unternehmen werden ihre gemeinsamen Daten auf der Jahrestagung der International Society of Cell & Gene Therapy (ISCT) in New Orleans vom 7. bis 10. Mai 2025 vorstellen.
- Integration of TcBuster and Flowfect technologies enables processing of billions of cells in minutes
- TcBuster system allows delivery of multiple genes simultaneously with high editing efficiency
- Combined technologies offer streamlined non-viral gene delivery process for faster therapeutic doses
- Platform suitable for various immune cell types, particularly non-dividing and apoptosis-sensitive cells
- None.
Insights
Bio-Techne partners with Kytopen to streamline cell therapy manufacturing with complementary non-viral gene delivery technologies, addressing key industry bottlenecks.
This strategic partnership between Bio-Techne and Kytopen combines two complementary technologies addressing critical bottlenecks in cell therapy manufacturing. The collaboration integrates Bio-Techne's TcBuster™ non-viral genome engineering system with Kytopen's Flowfect® continuous flow cellular engineering platform, creating a streamlined workflow with significant advantages over traditional methods.
The technical synergies are particularly noteworthy. Bio-Techne's TcBuster™ enables high-efficiency integration of large, multigene cargos in a single vector - a substantial improvement over conventional approaches. Meanwhile, Kytopen's Flowfect® technology provides gentle, high-throughput processing of billions of cells in minutes by combining mechanical, electrical, and chemical forces in a tunable system.
This partnership addresses a significant pain point in the cell therapy industry. Current viral vector-based engineering methods face limitations in manufacturing scale, cost, and safety profiles. The combined non-viral approach offers particular advantages for engineering immune cells that are non-dividing or sensitive to apoptosis - cell types that have historically been challenging to modify efficiently.
The GMP designation of both platforms positions them for clinical and commercial applications rather than just research use. This timing aligns with industry trends toward more efficient, scalable manufacturing solutions as more cell therapies progress through clinical development.
For Bio-Techne, this partnership enhances their cell and gene therapy tools portfolio in a high-growth market segment. While the immediate financial impact isn't quantifiable from the announcement alone, it represents a strategic expansion of capabilities in an area experiencing significant investment and development activity.
- Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing.
- The TcBuster™ system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect® continuous flow technology enables the gentle, high-efficiency processing of billions of cells in minutes.
- The companies' combined technologies deliver high gene insertion efficiencies and high cell viabilities, enabling a non-viral gene-editing workflow ideal for the development of advanced cell therapies.
- The data will be presented in a poster at ISCT, May 7-10, 2025, in
New Orleans .
Non-viral TcBuster offers numerous benefits over traditional lentivirus-based engineering methods. The hyperactive TcBuster transposase enables delivery of multiple genes simultaneously while maintaining high editing efficiency and a de-risked insertional profile. Flowfect® technology is a highly tunable system. It is unique in that it combines mechanical, electrical, and chemical forces, and allows the adjustment of multiple parameters to maximize transfection efficiency, cell health, and cell yield, while continuous flow enables the processing of hundreds of billions of healthy, high-quality engineered cells in just minutes. Together these technologies provide a streamlined gene delivery process that can achieve therapeutic doses quicker.
"We are excited about the opportunity to work with such a reputable life science provider as Bio-Techne", said Kevin Gutshall, Chief Commercial Officer at Kytopen, "Together our technologies offer a non-viral, gene-editing platform suitable for a range of immune cell types, in particular non-dividing cells and those sensitive to apoptosis, that will enable developers to bring more effective, advanced cell therapies to market quicker."
Data generated through the collaboration will be presented at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting, May 7-10, 2025, in
ISCT Poster Presentation. Wednesday, May 7, 2025, at 6:00pm; POSTER BOARD: 1105
CONTINUOUS FLOW TRANSFECTION WITH FLOWFECT® TECHNOLOGY AS AN EFFICIENT, NON-VIRAL TECHNOLOGY FOR SCALABLE CRISPR-MEDIATED ENGINEERING OF PRIMARY T CELLS
Global Showcase. 15 min Presentation, Thursday, May 8, 2025, at 6:00pm
A FULLY VALIDATED, NON-VIRAL GMP PLATFORM FOR THE MANUFACTURE OF ENGINEERED CELLS AT CLINICAL AND COMMERCIAL SCALE
For further information:
Kytopen:
Investor Contact:
Michael Chiu PhD., CEO
mchiu@kytopen.com
Business and Corporate Development Contact:
Kevin Gutshall, CCO
kgutshall@kytopen.com
About Kytopen:
The innovative leader in non-viral, continuous flow cellular engineering technologies, Kytopen, headquartered in
Bio-Techne
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
View original content to download multimedia:https://www.prnewswire.com/news-releases/kytopen-and-bio-techne-collaborate-on-an-integrated-cellular-engineering-workflow-to-expedite-cell-therapy-manufacturing-302449438.html
SOURCE Kytopen
FAQ
What is the partnership between Bio-Techne (TECH) and Kytopen focused on?
What are the key benefits of Bio-Techne's TcBuster system for cell therapy?
How does Kytopen's Flowfect technology enhance cell therapy manufacturing?
When and where will Bio-Techne and Kytopen present their collaboration data?
